Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Hold” by Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has been assigned an average recommendation of “Hold” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $42.2222.

A number of brokerages have issued reports on SION. JonesTrading cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. BTIG Research lowered Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $7.00 price objective on shares of Sionna Therapeutics in a research note on Monday, August 10th. Finally, Wedbush downgraded shares of Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research report on Monday, August 10th.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 403,524 shares of company stock worth $18,250,367. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SION. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics during the third quarter worth $30,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics in the second quarter valued at $31,000. State of Wyoming bought a new stake in Sionna Therapeutics during the second quarter valued at $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Sionna Therapeutics during the second quarter valued at $44,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Sionna Therapeutics during the 4th quarter worth about $58,000.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $7.85 on Friday. The company’s 50 day moving average price is $26.25 and its two-hundred day moving average price is $34.59. The firm has a market capitalization of $354.90 million, a P/E ratio of -3.60 and a beta of 0.89. Sionna Therapeutics has a fifty-two week low of $4.01 and a fifty-two week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, analysts expect that Sionna Therapeutics will post -2.55 earnings per share for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.